Cite

HARVARD Citation

    Kalff, A. et al. (2021). Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). Leukemia & lymphoma. 62 (12), pp. 2981-2991. [Online]. 
  
Back to record